Literature DB >> 31899415

Augmented Whole-Body Scanning via Magnifying PET.

Jianyong Jiang, Suranjana Samanta, Ke Li, Stefan B Siegel, Robert A Mintzer, Sanghee Cho, Maurizio Conti, Matthias Schmand, Joseph O'Sullivan, Yuan-Chuan Tai.   

Abstract

A novel technique, called augmented whole-body scanning via magnifying PET (AWSM-PET), that improves the sensitivity and lesion detectability of a PET scanner for whole-body imaging is proposed and evaluated. A Siemens Biograph Vision PET/CT scanner equipped with one or two high-resolution panel-detectors was simulated to study the effectiveness of AWSM-PET technology. The detector panels are located immediately outside the scanner's axial field-of-view (FOV). A detector panel contains 2 ×8 detector modules each consisting of 32 ×64 LSO crystals ( 1.0 ×1.0 ×10.0 mm3 each). A 22Na point source was stepped across the scanner's FOV axially to measure sensitivity profiles at different locations. An elliptical torso phantom containing 7×9 spherical lesions was imaged at different axial locations to mimic a multi-bed-position whole-body imaging protocol. Receiver operating characteristic (ROC) curves were analyzed to evaluate the improvement in lesion detectability by the AWSM-PET technology. Experimental validation was conducted using an existing flat-panel detector integrated with a Siemens Biograph 40 PET/CT scanner to image a torso phantom containing spherical lesions with diameters ranging from 3.3 to 11.4 mm. The contrast-recovery-coefficient (CRC) of the lesions was evaluated for the scanner with or without the AWSM-PET technology. Monte Carlo simulation shows 36%-42% improvement in system sensitivity by a dual-panel AWSM-PET device. The area under the ROC curve is 0.962 by a native scanner for the detection of 4 mm diameter lesions with 5:1 tumor-to-background activity concentration. It was improved to 0.977 and 0.991 with a single- and dual-panel AWSM-PET system, respectively. Experimental studies showed that the average CRC of 3.3 mm and 4.3 mm diameter tumors were improved from 2.8% and 4.2% to 7.9% and 11.0%, respectively, by a single-panel AWSM-PET device. With a high-sensitivity dual-panel device, the corresponding CRC can be further improved to 11.0% and 15.9%, respectively. The principle of the AWSM-PET technology has been developed and validated. Enhanced system sensitivity, CRC and tumor detectability were demonstrated by Monte Carlo simulations and imaging experiments. This technology may offer a cost-effective path to realize high-resolution whole-body PET imaging clinically.

Entities:  

Mesh:

Year:  2020        PMID: 31899415      PMCID: PMC7673659          DOI: 10.1109/TMI.2019.2962623

Source DB:  PubMed          Journal:  IEEE Trans Med Imaging        ISSN: 0278-0062            Impact factor:   10.048


  37 in total

Review 1.  Receiver operating characteristic (ROC) methodology: the state of the art.

Authors:  J A Hanley
Journal:  Crit Rev Diagn Imaging       Date:  1989

2.  Virtual-pinhole PET.

Authors:  Yuan-Chuan Tai; Heyu Wu; Debashish Pal; Joseph A O'Sullivan
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

Review 3.  Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature.

Authors:  Vahid Reza Dabbagh Kakhki; Sara Shahriari; Giorgio Treglia; Malihe Hasanzadeh; Seyed Rasoul Zakavi; Zohreh Yousefi; Sima Kadkhodayan; Ramin Sadeghi
Journal:  Int J Gynecol Cancer       Date:  2013-11       Impact factor: 3.437

4.  Adaptive imaging for lesion detection using a zoom-in PET system.

Authors:  Jian Zhou; Jinyi Qi
Journal:  IEEE Trans Med Imaging       Date:  2010-08-09       Impact factor: 10.048

Review 5.  Radiologist views of positron emission mammography.

Authors:  Lacey R Greene; Robert F George
Journal:  Radiol Technol       Date:  2012 Sep-Oct

6.  FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.

Authors:  Greet Swinnen; Alex Maes; Hans Pottel; Alain Vanneste; Ignace Billiet; Karl Lesage; Patrick Werbrouck
Journal:  Eur Urol       Date:  2009-05-18       Impact factor: 20.096

7.  A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection.

Authors:  P Som; H L Atkins; D Bandoypadhyay; J S Fowler; R R MacGregor; K Matsui; Z H Oster; D F Sacker; C Y Shiue; H Turner; C N Wan; A P Wolf; S V Zabinski
Journal:  J Nucl Med       Date:  1980-07       Impact factor: 10.057

8.  Feasibility study of a point-of-care positron emission tomography system with interactive imaging capability.

Authors:  Jianyong Jiang; Ke Li; Sergey Komarov; Joseph A O'Sullivan; Yuan-Chuan Tai
Journal:  Med Phys       Date:  2019-02-14       Impact factor: 4.071

9.  Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging.

Authors:  Kathy Schilling; Deepa Narayanan; Judith E Kalinyak; Juliette The; Maria Victoria Velasquez; Simone Kahn; Matthew Saady; Ravinder Mahal; Larraine Chrystal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-25       Impact factor: 9.236

10.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.